Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Preclinical and preliminary clinical data indicate that ch14.18, a monoclonal antibody against the tumor-associated disialoganglioside GD2, has activity against neuroblastoma and that such activity is enhanced when ch14.18 is combined with granulocyte-macrophage colony-stimulating factor (GM-CSF) or interleukin-2. We conducted a study to determine whether adding ch14.18, GM-CSF, and interleukin-2 to standard isotretinoin therapy after intensive multimodal therapy would improve outcomes in high-risk neuroblastoma. METHODS: Patients with high-risk neuroblastoma who had a response to induction therapy and stem-cell transplantation were randomly assigned, in a 1:1 ratio, to receive standard therapy (six cycles of isotretinoin) or immunotherapy (six cycles of isotretinoin and five concomitant cycles of ch14.18 in combination with alternating GM-CSF and interleukin-2). Event-free survival and overall survival were compared between the immunotherapy group and the standard-therapy group, on an intention-to-treat basis. RESULTS: A total of 226 eligible patients were randomly assigned to a treatment group. In the immunotherapy group, a total of 52% of patients had pain of grade 3, 4, or 5, and 23% and 25% of patients had capillary leak syndrome and hypersensitivity reactions, respectively. With 61% of the number of expected events observed, the study met the criteria for early stopping owing to efficacy. The median duration of follow-up was 2.1 years. Immunotherapy was superior to standard therapy with regard to rates of event-free survival (66±5% vs. 46±5% at 2 years, P=0.01) and overall survival (86±4% vs. 75±5% at 2 years, P=0.02 without adjustment for interim analyses). CONCLUSIONS: Immunotherapy with ch14.18, GM-CSF, and interleukin-2 was associated with a significantly improved outcome as compared with standard therapy in patients with high-risk neuroblastoma. (Funded by the National Institutes of Health and the Food and Drug Administration; ClinicalTrials.gov number, NCT00026312.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Some immunotherapies have shown promise in this setting, such as dinutuximab administered in combination with cytotoxic therapy in relapsed/refractory neuroblastoma3,4.”
From A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412 (2022) · cites this paper as [4]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310 · cited 1×
“Pain 50 (37) 30 (24) 23 (19) 33 (29) 15 (14) 4 (4)”
Discrete Sequential Boundaries for Clinical Trials
Lan, K. K. G., & DeMets, D. L. (1983) · Biometrika · doi:10.2307/2336502 · Cited by 2,310
Maris, J. M., Hogarty, M. D., Bagatell, R., & Cohn, S. L. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60983-0 · Cited by 2,032
Self-citationMatthay, K. K., Villablanca, J. G., Seeger, R. C., Stram, D. O., Harris, R. E., Ramsay, N. K., Swift, P., Shimada, H., Black, C. T., Brodeur, G. M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199910143411601 · Cited by 1,898 · cited 2×
“Hypersensitivity reaction 14 (10) 33 (26) 6 (5) 29 (25) 13 (12) 3 (3)”
Self-citationWeng, W.-K., & Levy, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.013 · Cited by 1,300 · cited 1×
“Complete response 38 (34) 40 (35) 78 (35) 61±7 86±5”
Musolino, A., Naldi, N., Bortesi, B., Pezzuolo, D., Capelletti, M., Missale, G., Laccabue, D., Zerbini, A., Camisa, R., Bisagni, G., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8957 · Cited by 981
Matthay, K. K., Reynolds, C. P., Seeger, R. C., Shimada, H., Adkins, E. S., Haas-Kogan, D., Gerbing, R. B., London, W. B., & Villablanca, J. G. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.8925 · Cited by 858 · cited 1×
“Pain 50 (37) 30 (24) 23 (19) 33 (29) 15 (14) 4 (4)”
Self-citationAdoptive cell therapy for the treatment of patients with metastatic melanoma
Rosenberg, S. A., & Dudley, M. E. (2009) · Current Opinion in Immunology · doi:10.1016/j.coi.2009.03.002 · Cited by 595
Research works printed but not linked: 10
- Schulz G, 1984, Cancer Res, 44, 5914
- Yu AL, 1997, Proc Am Soc Oncol, 6, 1846
- Barker E, 1991, Cancer Res, 51, 144
- Albertini MR, 1997, Clin Cancer Res, 3, 1277
- Hank JA, 1990, Cancer Res, 50, 5234
- 10.2307/2281868 · doi:10.2307/2281868 · Paper page
- Greenwood M, 1926, Rep Public Health Med Subj (Lond), 33, 1
- Barker E, 1993, Cancer Res, 53, 362
- Dallegri F, 1989, Clin Exp Immunol, 77, 58
- Simon T, 2009, Pediatr Blood Cancer, 53, 708
Cited by
Items 101–200 of 1,000
HDAC inhibitors and immunotherapy; a double edged sword?
Kroesen, M., Gielen, P. R., Brok, I. C., Armandari, I., Hoogerbrugge, P. M., & Adema, G. J. (2014) · Oncotarget · doi:10.18632/oncotarget.2289 · Cited by 166
“Immunotherapy is a promising novel cancer therapy for multiple cancer types, including melanoma and neuroblastoma[11, 12].”
BackgroundChoice of costimulatory domains and of cytokines determines CAR T-cell activity in neuroblastoma
Quintarelli, C., Orlando, D., Boffa, I., Guercio, M., Polito, V. A., Petretto, A., Lavarello, C., Sinibaldi, M., Weber, G., Del Bufalo, F., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1433518 · Cited by 163
Moghimi, B., Muthugounder, S., Jambon, S., Tibbetts, R., Hung, L., Bassiri, H., Hogarty, M. D., Barrett, D. M., Shimada, H., & Asgharzadeh, S. (2021) · Nature Communications · doi:10.1038/s41467-020-20785-x · Cited by 161
Self-citationClinical Cancer Therapy by NK Cells via Antibody‐Dependent Cell‐Mediated Cytotoxicity
Alderson, K. L., & Sondel, P. M. (2011) · BioMed Research International · doi:10.1155/2011/379123 · Cited by 156
“18 mAb with GM-CSF and IL2 regimen [39].”
Self-citationNavid, F., Sondel, P. M., Barfield, R., Shulkin, B. L., Kaufman, R. A., Allay, J. A., Gan, J., Hutson, P., Seo, S., Kim, K., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.4423 · Cited by 165
“18 combined with cytokines and isotretinoin in the maintenance phase had longer event-free and overall survival compared with those who received isotretinoin alone.(2) Similarly, in an update of the Cooperative German Neuroblastoma Trials, patients who received ch14.”
BackgroundResultSelf-citationPasquier, E., Street, J., Pouchy, C., Carre, M., Gifford, A. J., Murray, J., Norris, M. D., Trahair, T., Andre, N., & Kavallaris, M. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.205 · Cited by 162
“Moreover, these therapeutic options are all extremely aggressive and toxic (Ishola and Chung, 2007; Shusterman et al, 2010; Yu et al, 2010), suggesting that the limit of therapy intensification may have been reached.”
BackgroundSynthetic carbohydrate-based vaccines: challenges and opportunities
Mettu, R., Chen, C.-Y., & Wu, C. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-019-0591-0 · Cited by 176
“Thus, TACAs are demonstrated to be ideal targets for cancer vaccine development.”
BackgroundClinical impact of the NKp30/B7-H6 axis in high-risk neuroblastoma patients
Semeraro, M., Rusakiewicz, S., Minard-Colin, V., Delahaye, N. F., Enot, D., Vély, F., Marabelle, A., Papoular, B., Piperoglou, C., Ponzoni, M., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa2327 · Cited by 153
Ladenstein, R. L., Pötschger, U., Valteau‐Couanet, D., Luksch, R., Castel, V., Ash, S., Laureys, G., Brock, P. R., Michon, J. M., Owens, C., et al. (2020) · Cancers · doi:10.3390/cancers12020309 · Cited by 165
“As the disialoganglioside GD2 is expressed on the majority of neuroblastoma cells, with minimal expression on normal cells, it is a suitable target for immunotherapy [7].”
InfluentialCAR T Cell Therapy for Neuroblastoma
Richards, R. M., Sotillo, E., & Majzner, R. G. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02380 · Cited by 169
“A pivotal phase III clinical trial published in 2010 revealed an increase in 2 year EFS from 46 to 66% and overall survival (OS) from 75 to 86% for patients who received adjuvant anti-GD2 monoclonal antibody given with IL-2, GM-CSF, and retinoic acid compared to patients who received retinoic acid alone (6).”
BackgroundMethodCheung, N. V., Guo, H.-F., Hu, J., Tassev, D. V., & Cheung, I. Y. (2012) · OncoImmunology · doi:10.4161/onci.19864 · Cited by 166
Disialoganglioside GD2 as a therapeutic target for human diseases
Suzuki, M., & Cheung, N. V. (2015) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.986459 · Cited by 162
“18 in combination with GM-CSF and IL-2 in patients with HR neuroblastoma, demonstrating significant improvement in OS when compared to no immunotherapy [1].”
BackgroundInfluentialTargeting Tumor-Infiltrating Macrophages to Combat Cancer
Panni, R. Z., Linehan, D. C., & DeNardo, D. G. (2013) · Immunotherapy · doi:10.2217/imt.13.102 · Cited by 152
Mulrooney, D. A., Hyun, G., Ness, K. K., Ehrhardt, M. J., Yasui, Y., Duprez, D. A., Howell, R. M., Leisenring, W. M., Constine, L. S., Tonorezos, E. S., et al. (2020) · BMJ · doi:10.1136/bmj.l6794 · Cited by 169
Goldsmith, K. C., Park, J. R., Kayser, K., Malvar, J., Chi, Y., Groshen, S. G., Villablanca, J. G., Krytska, K., Lai, L. M., Acharya, P. T., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02297-5 · Cited by 163
“…genomics and immune evasion, a child diagnosed with high-risk neuroblastoma today is subjected to a largely empiric and vastly intensive regimen of genotoxic chemotherapeutics, radiation and GD2-targeted immunotherapy that, although effective, has substantial acute and long-term side effects 30 .”
Self-citationEngineering anti‐GD2 monoclonal antibodies for cancer immunotherapy
Ahmed, M., & Cheung, N. V. (2013) · FEBS Letters · doi:10.1016/j.febslet.2013.11.030 · Cited by 159
“Observed toxicities were similar to what is observed with IL-2 alone, including capillary leak syndrome and abnormal liver functions [44,67].”
BackgroundMethodTrial Watch: Monoclonal antibodies in cancer therapy
Galluzzi, L., Vacchelli, E., Fridman, W. H., Galon, J., Sautès-Fridman, C., Tartour, E., Zucman-Rossi, J., Zitvogel, L., & Kroemer, G. (2012) · OncoImmunology · doi:10.4161/onci.1.1.17938 · Cited by 149
Oncotargets GD2 and GD3 are highly expressed in sarcomas of children, adolescents, and young adults
Dobrenkov, K., Ostrovnaya, I., Gu, J., Cheung, I. Y., & Cheung, N. V. (2016) · Pediatric Blood & Cancer · doi:10.1002/pbc.26097 · Cited by 149
Morris, Z. S., Guy, E. I., Francis, D. M., Gressett, M. M., Werner, L. R., Carmichael, L. L., Yang, R. K., Armstrong, E. A., Huang, S., Navid, F., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2644 · Cited by 160
“org Cancer Res; 76(13) July 1, 2016 OF5”
BackgroundInfluentialSelf-citationDinutuximab: First Global Approval
Dhillon, S. (2015) · Drugs · doi:10.1007/s40265-015-0399-5 · Cited by 155
“At a median follow-up of 2.1 months, dinutuximab recipients (n = 113 intent to treat) had significantly higher EFS rates (66 vs. 46 %; p = 0.01) and overall survival (OS) rates (86 vs. 75 %; p = 0.02) compared with standard therapy recipients (n = 113 intent to treat) in a randomized, open-label, phase III study (NCT0…”
BackgroundMethodResultInfluentialPerspectives on Anti-Glycan Antibodies Gleaned from Development of a Community Resource Database
Sterner, E., Flanagan, N., & Gildersleeve, J. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00244 · Cited by 147
Kushner, B. H., Cheung, I. Y., Modak, S. I., Kramer, K., Ragupathi, G., & Cheung, N. V. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1012 · Cited by 147
“Our Clin Cancer Res; 20(5) March 1, 2014 Clinical Cancer Research1380 bivalent vaccine is constructedwith the purpose of inducing host anti-ganglioside antibodies that can replicate the antineoplastic effects of exogenously administered MoAbs.”
BackgroundInfluentialSholler, G. L. S., Gerner, E. W., Bergendahl, G., MacArthur, R. B., VanderWerff, A., Ashikaga, T., Bond, J. P., Ferguson, W. S., Roberts, W. D., Wada, R. K., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0127246 · Cited by 152
Kailayangiri, S., Altvater, B., Meltzer, J., Pscherer, S., Luecke, A., Dierkes, C., Titze, U., Leuchte, K., Landmeier, S., Hotfilder, M., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.57 · Cited by 142
“In high-risk neuroblastoma, a highly GD2-expressing malignancy, immunotherapy with a chimeric GD2-specific antibody combined with GM-CSF and IL-2 significantly improved event-free survival (Yu et al, 2010).”
BackgroundInfluentialHarnessing the Immunotherapy Revolution for the Treatment of Childhood Cancers
Majzner, R. G., Heitzeneder, S., & Mackall, C. L. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.03.002 · Cited by 151
Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy
Joshi, S., & Sharabi, A. B. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108114 · Cited by 154
Targeting Tumor Glycans for Cancer Therapy: Successes, Limitations, and Perspectives
Berois, N., Pittini, Á., & Osinaga, E. (2022) · Cancers · doi:10.3390/cancers14030645 · Cited by 154
“Several anti-GD2 mAbs have been successfully tested in clinical practice, including chimeric 14.18 (ch 14.18) (NCT00026312) [36], humanized 14.18 (hu 14.18) [37], and humanized 3F8 (hu3F8) [38,39].”
BackgroundInfluentialHenderson, T. O., Bhatia, R., Pinto, N. R., London, W. B., McGrady, P., Crotty, C., Sun, C., & Cohn, S. L. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.6103 · Cited by 154
Self-citationYalçın, B., Kremer, L. C. M., & van Dalen, E. C. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006301.pub4 · Cited by 148
Engineering IL-2 to Give New Life to T Cell Immunotherapy
Overwijk, W. W., Tagliaferri, M. A., & Zalevsky, J. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-073118-011031 · Cited by 142
Neuroblastoma (Peripheral neuroblastic tumours)
Luksch, R., Castellani, M. R., Collini, P., Bernardi, B. D., Conte, M., Gambini, C., Gandola, L., Garaventa, A., Biasoni, D., Podda, M. G., et al. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.10.001 · Cited by 148
Li, N., Fu, H., Hewitt, S. M., Dimitrov, D. S., & Ho, M. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1706055114 · Cited by 172
Holmes, K., Pötschger, U., Pearson, A. D. J., Sarnacki, S., Cecchetto, G., Gómez-Chacón, J., Squire, R., Freud, E., Bysiek, A., Matthyssens, L., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03117 · Cited by 142
Tran, H. C., Wan, Z., Sheard, M. A., Sun, J., Jackson, J. R., Malvar, J., Xu, Y., Wang, L., Sposto, R., Kim, E. S., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1743 · Cited by 132
“Galunisertib decreases suppression of aNK cells by TGFb1 Having established that galunisertib reduces SMAD activity in neuroblastoma cells, we examined whether it might reduce the effects of TGFb1 on aNK cells.”
BackgroundInfluentialSelf-citationNeuroblastoma: When differentiation goes awry
Zeineldin, M., Patel, A. G., & Dyer, M. A. (2022) · Neuron · doi:10.1016/j.neuron.2022.07.012 · Cited by 138
Mabe, N. W., Huang, M., Dalton, G. N., Alexe, G., Schaefer, D. A., Geraghty, A. C., Robichaud, A. L., Conway, A. S., Khalid, D., Mader, M. M.-D., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00405-x · Cited by 150
“Wells received one of four treatment cohorts in triplicate (48 h) or quadruplicate (8 h): (1) human isotype antibody (1 μg ml−1), (2) dinutuximab (1 μg ml−1), (3) human isotype (1 μg ml−1) with 1:2 (NK/tumor cell) ratio or (4) dinutuximab (1 μg ml−1) with 1:2 (NK/tumor cell) ratio.”
BackgroundMethodKushner, B. H., Cheung, I. Y., Modak, S. I., Basu, E. M., Roberts, S. S., & Cheung, N. V. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.4005 · Cited by 132
“Patients received a median (range) of 4 (1-15) cycles of hu3F8 and GM-CSF.”
BackgroundMethodInfluentialWang, K., Chen, Y., Ahn, S., Zheng, M., Landoni, E., Dotti, G., Savoldo, B., & Han, Z. (2020) · Nature Cancer · doi:10.1038/s43018-020-00119-y · Cited by 132
Twist, C. J., Schmidt, M. L., Naranjo, A. H., London, W. B., Tenney, S. C., Marachelian, A., Shimada, H., Collins, M. H., Esiashvili, N., Adkins, E. S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00919 · Cited by 131
Self-citationNew Strategies in Neuroblastoma: Therapeutic Targeting of MYCN and ALK
Barone, G., Anderson, J., Pearson, A. D. J., Petrie, K. R., & Chesler, L. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0680 · Cited by 145
“18 chimeric antibody in combination with the cytokines GM-CSF and IL2 during continuation therapy has improved two-year progression-free survival (from time of randomization) by 20% (2).”
Recent progress in the treatment of cancer in children
Butler, E. B., Ludwig, K. F., Pacenta, H. L., Klesse, L. J., Watt, T. C., & Laetsch, T. W. (2021) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21665 · Cited by 156
Pui, C.-H., Pei, D., Pappo, A. S., Howard, S. C., Cheng, C., Sandlund, J. T., Furman, W. L., Ribeiro, R. C., Spunt, S. L., Rubnitz, J. E., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.8617 · Cited by 128
“Immunotherapy with the monoclonal antibody anti-GD2 with granulocyte-macrophage colony-stimulating factor, interleukin-2, and isotretinoin has also significantly improved the survival of patients with high-risk neuroblastoma treated in a recent COG study.(38) These therapeutic gains have benefited black and white chil…”
BackgroundIncidence, Survival, and Treatment of Localized and Metastatic Neuroblastoma in Germany 1979–2015
Berthold, F., Spix, C., Kaatsch, P., & Lampert, F. H. (2017) · Pediatric Drugs · doi:10.1007/s40272-017-0251-3 · Cited by 129
Wienke, J., Visser, L. L., Kholosy, W. M., Keller, K. M., Barisa, M., Poon, E., Munnings-Tomes, S., Himsworth, C., Calton, E. A., Rodríguez, A. I. E., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2023.12.008 · Cited by 138
Simon, T., Hero, B., Faldum, A., Handgretinger, R., Schrappe, M., Klingebiel, T., & Berthold, F. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-21 · Cited by 132
“The randomized COG trial ANBL0032 was stopped after interim analysis because the antibody-containing arm was more effective than the retinoic acid standard arm [21]: Stage 4 neuroblastoma patients one year or older who received the immunotherapy combination had a better outcome (2-year EFS rate from randomization 63 ±…”
BackgroundTargets and Antibody Formats for Immunotherapy of Neuroblastoma
Park, J. A., & Cheung, N. V. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01410 · Cited by 136
“18-K322A, have produced long-term cures among patients with highrisk metastatic NB. Antibody engineering through humanization and Fc modification to optimize their structure and function can reduce immunogenicity, improve effectiveness, and decrease on-target off-tumor adverse effects.67,98,99 Engaging T cells using T…”
BackgroundResultInfluentialOvercoming Heterogeneity of Antigen Expression for Effective CAR T Cell Targeting of Cancers
Kailayangiri, S., Altvater, B., Wiebel, M., Jamitzky, S., & Rössig, C. (2020) · Cancers · doi:10.3390/cancers12051075 · Cited by 137
“As a marker of immature neuroectodermal cells, GD2 is abundantly surface-expressed in neuroblastoma which originates from undifferentiated neuroectoderm [50,51].”
BackgroundImmune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy
Kaczanowska, S., Murty, T., Alimadadi, A., Contreras, C. F., Duault, C., Subrahmanyam, P. B., Reynolds, W. D., Gutierrez, N. A., Baskar, R., Wu, C. J., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.11.011 · Cited by 134
The Future Is Now: Chimeric Antigen Receptors as New Targeted Therapies for Childhood Cancer
Lee, D. W., Barrett, D. M., Mackall, C., Orentas, R., & Grupp, S. A. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1920 · Cited by 127
Self-citationEZH2 Inhibition in Ewing Sarcoma Upregulates GD2 Expression for Targeting with Gene-Modified T Cells
Kailayangiri, S., Altvater, B., Lesch, S., Balbach, S. T., Göttlich, C., Kühnemundt, J., Mikesch, J., Schelhaas, S., Jamitzky, S., Meltzer, J., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.02.014 · Cited by 131
Protein glycosylation in cancers and its potential therapeutic applications in neuroblastoma
Ho, W., Hsu, W., Huang, M., Kadomatsu, K., & Nakagawara, A. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0334-6 · Cited by 127
“myeloablative therapy and stem-cell rescue [99].”
Effect of Natural Compounds on NK Cell Activation
Grudzień, M., & Rapak, A. (2018) · Journal of Immunology Research · doi:10.1155/2018/4868417 · Cited by 139
Lou, Y., Wang, P.-Y., Yeh, S.-C., Chuang, P., Li, S.-T., Wu, C., Khoo, K., Hsiao, M., Hsu, T.-L., & Wong, C. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1400283111 · Cited by 130
Cherny, N. I., de Vries, E. G. E., Dafni, U. G., Garrett-Mayer, E. S., McKernin, S. E., Piccart, M. J., Latino, N. J., Douillard, J.-Y., Schnipper, L. E., Somerfield, M. R., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00729 · Cited by 130
“One was listed twice, and four were identified as not suitable for scoring with ASCO-NHB v2 for the following reasons: nonrandomized study (n = 1),(15) noninferiority study with benefit not evaluable by ASCO (n = 1),(16) and unconventional designs in a curative setting (n = 2).(17,18) Among the 104 trials evaluated, s…”
Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution
Tzeng, A., Kwan, B. H., Opel, C. F., Navaratna, T., & Wittrup, K. D. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1416159112 · Cited by 122
Immunotherapy of Neuroblastoma: Facts and Hopes
Anderson, J., Majzner, R. G., & Sondel, P. M. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1356 · Cited by 142
“Patients receiving the immunotherapy showed improved event-free survival (EFS) and overall survival (OS) initially, and after nearly a decade of follow-up (23, 29).”
InfluentialSelf-citationCurrent and Emerging Targets in Immunotherapy for Osteosarcoma
Miwa, S., Shirai, T., Yamamoto, N., Hayashi, K., Takeuchi, A., Igarashi, K., & Tsuchiya, H. (2019) · Journal of Oncology · doi:10.1155/2019/7035045 · Cited by 122
Wei, J. S., Kuznetsov, I. B., Zhang, S., Song, Y., Asgharzadeh, S., Sindiri, S., Wen, X., Patidar, R., Najaraj, S., Walton, A., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0599 · Cited by 131
“CD8 expression was scored as (0) none, (1) rare scatted CD8þ cells (less than 5), (2) occasional CD8þ cells (less than10), (3) aggregates ofCD8þ cells, 10ormore cellswith only a single aggregate of 2 or more CD8þ cells within 10 mm proximity to each other, and (4) multiple aggregates of CD8þ cells.”
BackgroundSelf-citationBocca, P., Di Carlo, E., Caruana, I., Emionite, L., Cilli, M., De Angelis, B., Quintarelli, C., Pezzolo, A., Raffaghello, L., Morandi, F., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2017.1378843 · Cited by 119
“GD2 is a disialoganglioside highly expressed on human NB cells that represents a good target for NB immunotherapy.(5) GD2-redirected CAR T cells (GD2CAR T) represent a new therapeutic option for GD2C tumors,”
BackgroundImmunologic biomarkers as correlates of clinical response to cancer immunotherapy
Disis, M. L. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0960-8 · Cited by 120
“Trafficking T cells secreting IFN-c could activate local tumor APC, restore key functions and upregulate immune accessory molecules, which would enhance cross-priming.”
BackgroundMethodInfluentialFisher, J. P. H., Yan, M., Heuijerjans, J., Carter, L., Abolhassani, A., Frosch, J., Wallace, R., Flutter, B. R., Capsomidis, A., Hubank, M. J. F., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3464 · Cited by 119
“18 anti-GD2 mAb (16, 28, 29), and sensitivity of neuroblastoma cells to killing by Vg9Vd2þ gdT cells (31).”
BackgroundThe role of tumor-associated macrophages in osteosarcoma progression – therapeutic implications
Huang, Q., Liang, X., Ren, T., Huang, Y., Zhang, H., Yu, Y., Chen, C., Wang, W., Niu, J., Lou, J., et al. (2021) · Cellular Oncology · doi:10.1007/s13402-021-00598-w · Cited by 118
Parikh, N. S., Howard, S. C., Chantada, G. L., Israëls, T., Khattab, M., Alcasabas, P., Lam, C. G., Faulkner, L., Park, J. R., London, W. B., et al. (2015) · Pediatric Blood & Cancer · doi:10.1002/pbc.25501 · Cited by 126
“The relapse rate of greater than 40% even after such therapies has led to post-transplant treatment for MRD-positive patients using isotretinoin and monoclonal anti-GD2 antibodies [39,58,59].”
BackgroundSelf-citationCheung, I. Y., Cheung, N. V., Modak, S. I., Mauguen, A., Feng, Y., Basu, E. M., Roberts, S. S., Ragupathi, G., & Kushner, B. H. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.01892 · Cited by 123
“With the integration of anti-disialoganglioside (GD)2 monoclonal antibody (mAb) into the standard of care, 50%-60% of children with high-risk neuroblastoma (HR-NB) are long-term survivors.(4,5) Successful vaccines could induce a protective antitumor immune response.”
BackgroundNeuroblastoma treatment in the post-genomic era
Esposito, M. R., Aveic, S., Seydel, A., & Tonini, G. P. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-017-0319-y · Cited by 124
“18 anti-GD2 antibody (NCT00026312; list of all clinical trials discussed here can be found in Table 1) [6]; ii) a phase III randomized study (SIOPEN) for isotretinoin (13-cis-RA) and ch14.”
High-Risk and Relapsed Neuroblastoma: Toward More Cures and Better Outcomes
DuBois, S. G., Macy, M. E., & Henderson, T. O. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_349783 · Cited by 152
Mussai, F., Egan, S. A., Hunter, S., Webber, H. T., Fisher, J. P. H., Wheat, R. L., McConville, C. M., Sbirkov, Y., Wheeler, K., Bendle, G. M., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3443 · Cited by 124
“(6,7) Immunotherapeutic approaches are reliant on an active immune system, therefore one likely hypothesis for their failure is that neuroblastoma creates an immunosuppressive microenvironment that inhibits autologous or adoptive immunity.”
Ryan, J., Tivnan, A., Fay, J., Bryan, K. R., Meehan, M., Creevey, L., Lynch, J., Bray, I. M., O’Meara, A., Davidoff, A. M., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.356 · Cited by 122
“…therapeutic approaches such as anti-GD2 immunotherapy have improved patient survival rates (2-year event-free survival (EFS) of 66% reported in high-risk neuroblastoma), 5-year survival rates are currently not available and this therapy has considerable deleterious side effects (Yu et al, 2010).”
BackgroundBarrett, D. M., Liu, X., Jiang, S., June, C. H., Grupp, S. A., & Zhao, Y. (2013) · Human Gene Therapy · doi:10.1089/hum.2013.075 · Cited by 110
“…the immediate-type hypersensitivity or triggered cytokine storms seen in some reported adverse events, it may avoid chronic complications such as the pain seen during infusions of anti-GD2 antibody therapy for neuroblastoma (in the case of anti-GD2 CARs) (Cooper et al., 2004; Yu et al., 2010).”
BackgroundSelf-citationMossé, Y. P., Deyell, R. J., Berthold, F., Nagakawara, A., Ambros, P. F., Monclair, T. F., Cohn, S. L., Pearson, A. D. J., London, W. B., & Matthay, K. K. (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24777 · Cited by 114
“Improvements in survival for high-risk neuroblastoma patients have resulted from an intensivemulti-modality approach to therapy, which includes multi-agent chemotherapy, surgery, consolidation with AHCT, radiotherapy and maintenance with isotretinoin and immunotherapy [25,26].”
BackgroundSelf-citationGargett, T., Ebert, L. M., Truong, N. T., Kollis, P. M., Šediváková, K., Yu, W., Yeo, E. C. F., Wittwer, N. L., Gliddon, B. L., Tea, M. N., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005187 · Cited by 121
“As the donor of the same antigen binding region as US FDA-approved dinutuximab, 15 the 14g2a mAb also supplies the scFvs employed in GD2-CARs of this study.”
Landier, W., Knight, K. R., Wong, F. L., Lee, J., Thomas, O., Kim, H., Kreissman, S. G., Schmidt, M. L., Chen, L., London, W. B., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.2038 · Cited by 120
Self-citationCazet, A., Bobowski, M., Rombouts, Y., Lefebvre, J., Steenackers, A., Popa, I., Guérardel, Y., Bourhis, X. L., Tulasne, D., & Delannoy, P. (2012) · Glycobiology · doi:10.1093/glycob/cws049 · Cited by 118
Pediatric Cancer Immunotherapy: Opportunities and Challenges
Wedekind, M. F., Denton, N. L., Chen, C., & Cripe, T. P. (2018) · Pediatric Drugs · doi:10.1007/s40272-018-0297-x · Cited by 121
“The pivotal study was performed by COG, which found an improved 2-year EFS of 64% compared with 44% with retinoic acid alone when given in combination with IL-2 and granulocyte monocyte colony stimulating factor [45].”
MethodFurman, W. L., McCarville, B., Shulkin, B. L., Davidoff, A. M., Krasin, M., Hsu, C.-W., Pan, H., Wu, J., Brennan, R., Bishop, M. W., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01375 · Cited by 111
“18K322A (40 mg/m(2) once per day for 4 days) was administered in place of dinutuximab.(1) Adverse events were assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.”
BackgroundMethodSelf-citationTreatment of Retinoblastoma: What Is the Latest and What Is the Future
Schaiquevich, P. S., Francis, J. H., Cancela, M. B., Carcaboso, A. M., Chantada, G. L., & Abramson, D. H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.822330 · Cited by 134
Liu, Y., Wu, H.-W., Sheard, M. A., Sposto, R., Somanchi, S. S., Cooper, L. J. N., Lee, D. A., & Seeger, R. C. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1243 · Cited by 121
“clinical response after induction chemotherapy and myeloablative consolidation therapy (3).”
Self-citationMaintenance DFMO Increases Survival in High Risk Neuroblastoma
Sholler, G. L. S., Ferguson, W. S., Bergendahl, G., Bond, J. P., Neville, K. A., Eslin, D. E., Brown, V. I., Roberts, W. D., Wada, R. K., Oesterheld, J. E., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-32659-w · Cited by 109
GD2‐targeted immunotherapy and potential value of circulating microRNAs in neuroblastoma
Gholamin, S., Mirzaei, H., Razavi, S., Hassanian, S. M., Saadatpour, L., Masoudifar, A., ShahidSales, S., & Avan, A. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.25793 · Cited by 105
“Hence, peripheral nerves and melanocytes can be suitable target for systemic tumor immunotherapy (Yu et al., 2010; Yang & Sondel, 2010).”
BackgroundCOX/mPGES-1/PGE 2 pathway depicts an inflammatory-dependent high-risk neuroblastoma subset
Larsson, K., Kock, A., Idborg, H., Arsenian‐Henriksson, M., Martinsson, T., Johnsen, J. I., Korotkova, M., Kogner, P., & Jakobsson, P. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1424355112 · Cited by 116
“Disialoganglioside (GD2) is expressed almost exclusively on tumors of neuroectodermal origin and is used as therapeutic target in neuroblastoma (30).”
Background2017 GPOH Guidelines for Diagnosis and Treatment of Patients with Neuroblastic Tumors
Simon, T., Hero, B., Schulte, J. H., Deubzer, H. E., Hundsdoerfer, P., von Schweinitz, D., Fuchs, J., Schmidt, M. C., Prasad, V., Krug, B., et al. (2017) · Klinische Pädiatrie · doi:10.1055/s-0043-103086 · Cited by 132
“18/SP2/0 antiGD2 antibody (Dinutuximab), CSF2 (formerly granulocyte-macrophage colony-stimulating factor or GM-CSF), interleukin 2 (IL2) and isotretinoin is considered the standard of care in the USA for first-line treatment of high-risk neuroblastoma [208].”
BackgroundAlvarez-Rueda, N., Desselle, A., Cochonneau, D., Chaumette, T., Clemenceau, B., Leprieur, S., Bougras-Cartron, G., Supiot, S., Mussini, J. M., Barbet, J., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025220 · Cited by 111
“18 antibody and cytokines with the standard therapy significantly improved outcome [4].”
BackgroundInfluentialMilestones in the Curability of Pediatric Cancers
Hudson, M. M., Link, M. P., & Simone, J. V. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.6571 · Cited by 116
Bottino, C., Dondero, A., Bellora, F., Moretta, L., Locatelli, F., Pistoia, V., Moretta, A., & Castriconi, R. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00056 · Cited by 108
“Interestingly, the antibodymediated targeting of the oncofetal differentiation antigen GD2 in combination with GM-CSF and IL-2 resulted in an improved outcome of patients and has been recently included in the standard care of high-risk NB (15).”
BackgroundAvoidance of On-Target Off-Tumor Activation Using a Co-stimulation-Only Chimeric Antigen Receptor
Fisher, J. P. H., Abramowski, P., Don, N. D. W., Flutter, B. R., Capsomidis, A., Cheung, G. W.-K., Gustafsson, K. T., & Anderson, J. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.002 · Cited by 110
Targeted inhibition of histone H3K27 demethylation is effective in high-risk neuroblastoma
Lochmann, T. L., Powell, K. M., Ham, J., Floros, K. V., Heisey, D. A. R., Kurupi, R., Calbert, M. L., Ghotra, M. S., Greninger, P., Dozmorov, M. G., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aao4680 · Cited by 111
Self-citationTNM Staging in Colorectal Cancer: T Is for T Cell and M Is for Memory
Broussard, E. K., & Disis, M. L. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.9078 · Cited by 100
Combination Strategies to Enhance Antitumor ADCC
Kohrt, H. E. K., Houot, R., Marabelle, A., Cho, H. J., Osman, K., Goldstein, M. J., Levy, R., & Brody, J. (2012) · Immunotherapy · doi:10.2217/imt.12.38 · Cited by 111
Steentoft, C., Migliorini, D., King-Peoples, T. R., Mandel, U., June, C. H., & Posey, A. D. (2018) · Glycobiology · doi:10.1093/glycob/cwy008 · Cited by 105
New drugs for children and adolescents with cancer: the need for novel development pathways
Vassal, G., Zwaan, C. M., Ashley, D. M., Deley, M. L., Hargrave, D. R., Blanc, P., & Adamson, P. C. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70013-5 · Cited by 104
Coughlan, D., Gianferante, M., Lynch, C. F., Stevens, J. L., & Harlan, L. C. (2017) · Pediatric Hematology and Oncology · doi:10.1080/08880018.2017.1373315 · Cited by 101
“[18] The results of the phase III randomized study of dinutuximab in high-risk neuroblastoma following myeloablative therapy and autologous stem cell rescue (NCT00026312) published in 2010 showed a superior outcome for the treatment-arm patients (n = 113) who received this immunotherapy-based treatment compared to sta…”
BackgroundTuning the ignition of CAR: optimizing the affinity of scFv to improve CAR-T therapy
Duan, Y., Chen, R., Huang, Y., Meng, X., Chen, J., Liao, C., Tang, Y., Zhou, C., Gao, X., & Sun, J. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-04089-x · Cited by 110
“Although several anti-GD2 mAbs have been developed to target solid tumors especially neuroblastoma, clinical trials found limited responses and nearly half of the patients with neuroblastoma would relapse [57, 58].”
BackgroundGeneration of anti-GD2 CAR macrophages from human pluripotent stem cells for cancer immunotherapies
Zhang, J., Webster, S. F., Duffin, B. M., Bernstein, M. N., Steill, J., Swanson, S. A., Forsberg, M. H., Bolin, J. M., Brown, M. E., Majumder, A., et al. (2023) · Stem Cell Reports · doi:10.1016/j.stemcr.2022.12.012 · Cited by 101
Flynn, M. J., & Hartley, J. A. (2017) · British Journal of Haematology · doi:10.1111/bjh.14770 · Cited by 99
Trial watch: Monoclonal antibodies in cancer therapy
Vacchelli, E., Eggermont, A. M. M., Galon, J., Sautès‐Fridman, C., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2012) · OncoImmunology · doi:10.4161/onci.22789 · Cited by 107
Sengupta, S., Das, S., Crespo, Â. C., Cornel, A. M., Patel, A. G., Mahadevan, N. R., Campisi, M., Ali, A. K., Sharma, B., Rowe, J. H., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00427-5 · Cited by 106
“2 ), has substantially improved survival rates in high-risk patients 3 .”
BackgroundMicroenvironmental Heterogeneity in Brain Malignancies
Perus, L. J. M., & Walsh, L. A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02294 · Cited by 106
“In the context of other brain malignancies, immunotherapy has already become part of common clinical practice with Dinutuximab, a monoclonal antibody against GD2 administered in conjunction with GMCSF, IL-2, and retinoic acid having been approved for postconsolidation therapy in high-risk neuroblastoma patients (160).”
BackgroundFurman, W. L., Federico, S. M., McCarville, M. B., Shulkin, B. L., Davidoff, A. M., Krasin, M. J., Sahr, N. A., Sykes, A. D., Wu, J., Brennan, R. C., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1452 · Cited by 96
“18K322A (40 mg/m(2) per day for 4 days) for dinutuximab (1).”
BackgroundResultSelf-citationVillablanca, J. G., Volchenboum, S. L., Cho, H., Kang, M. H., Cohn, S. L., Anderson, C. P., Marachelian, A., Groshen, S. G., Tsao-Wei, D. D., Matthay, K. K., et al. (2016) · Pediatric Blood & Cancer · doi:10.1002/pbc.25994 · Cited by 101
“Received 16 December 2015; Accepted 3 March 2016 idation, radiotherapy, isotretinoin, and immunotherapy.[1,2] Current myeloablative regimens for high-risk neuroblastoma often include melphalan (l-phenylalanine mustard).”
BackgroundSelf-citationZamora, A. E., Crawford, J. C., Allen, E. K., Guo, X.-Z. J., Bakke, J., Carter, R. A., Abdelsamed, H. A., Moustaki, A., Li, Y., Chang, T., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aat8549 · Cited by 100
Metadata
- Authors
- Yu, A. L., Gilman, A. L., Ozkaynak, M. F., London, W. B., Kreissman, S. G., Chen, H. X., Smith, M., Anderson, B., Villablanca, J. G., Matthay, K. K., Shimada, H., Grupp, S. A., Seeger, R., Reynolds, C. P., Buxton, A., Reisfeld, R. A., Gillies, S. D., Cohn, S. L., Maris, J. M., & Sondel, P. M.
- Affiliations
- University of California San Diego (US)
- Levine Children's Hospital (US)
- Boston Children's Hospital (US)
- Duke Medical Center (US)
- National Institutes of Health (US)
- University of Southern California (US)
- University of California, San Francisco (US)
- Children's Hospital of Philadelphia (US)
- Texas Tech University (US)
- Children's Oncology Group (US)
- Scripps Research Institute (US)
- University of Chicago (US)
- University of Wisconsin–Madison (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-09-30
- Volume
- 363
- Issue
- 14
- Pages
- 1324-1334
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3086629
- OpenAlex
- W2130465135
- Cited by
- 1,835
- References
- 38
- Citations by year
- 2026: 99 · 2025: 98 · 2024: 124 · 2023: 133 · 2022: 142 · 2021: 151 · 2020: 156 · 2019: 107 · 2018: 107 · 2017: 139 · 2016: 105 · 2015: 115 · 2014: 95 · 2013: 103 · 2012: 92
- FWCI
- 49.55
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (CA98543)
- U.S. Food and Drug Administration (FD-R-002319)
- National Cancer Institute (CA‐98413, U10 CA-98413, U10-CA98543, U10CA098413, R01CA032685, U10CA29139, U10CA029139, U10CA098543, CA-98543)
- Topics
- Health Sciences › Medicine › Oncology › Neuroblastoma Research and Treatments
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Health Sciences › Medicine › Clinical Neurology › Neurofibromatosis and Schwannoma Cases
- Keywords
- neuroblastoma, GD2, GM-CSF, interleukin-2, isotretinoin, immunotherapy, high-risk neuroblastoma, event-free survival, overall survival, disialoganglioside, stem cell transplantation, multimodal therapy
- MeSH terms
- Antibodies, Monoclonal, Antineoplastic Agents, Child, Child, Preschool, Combined Modality Therapy, Drug Therapy, Combination, Gangliosides, Humans, Immunotherapy, Infant, Interleukin-2, Neuroblastoma, Isotretinoin, Survival Analysis, Granulocyte-Macrophage Colony-Stimulating Factor, Stem Cell Transplantation, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.